These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21872125)

  • 1. Evaluation of an MRI-based score of disease activity in perianal fistulizing Crohn's disease.
    Horsthuis K; Ziech ML; Bipat S; Spijkerboer AM; de Bruine-Dobben AC; Hommes DW; Stoker J
    Clin Imaging; 2011; 35(5):360-5. PubMed ID: 21872125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease.
    Van Assche G; Vanbeckevoort D; Bielen D; Coremans G; Aerden I; Noman M; D'Hoore A; Penninckx F; Marchal G; Cornillie F; Rutgeerts P
    Am J Gastroenterol; 2003 Feb; 98(2):332-9. PubMed ID: 12591051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term monitoring of infliximab therapy for perianal fistulizing Crohn's disease by using magnetic resonance imaging.
    Karmiris K; Bielen D; Vanbeckevoort D; Vermeire S; Coremans G; Rutgeerts P; Van Assche G
    Clin Gastroenterol Hepatol; 2011 Feb; 9(2):130-6. PubMed ID: 21056696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic contrast-enhanced MRI in determining disease activity in perianal fistulizing Crohn disease: a pilot study.
    Ziech ML; Lavini C; Bipat S; Ponsioen CY; Spijkerboer AM; Stokkers PC; Nederveen AJ; Stoker J
    AJR Am J Roentgenol; 2013 Feb; 200(2):W170-7. PubMed ID: 23345381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.
    Bouguen G; Siproudhis L; Gizard E; Wallenhorst T; Billioud V; Bretagne JF; Bigard MA; Peyrin-Biroulet L
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):975-81.e1-4. PubMed ID: 23376316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical advantages of combined seton placement and infliximab maintenance therapy for perianal fistulizing Crohn's disease: when and how were the seton drains removed?
    Tanaka S; Matsuo K; Sasaki T; Nakano M; Sakai K; Beppu R; Yamashita Y; Maeda K; Aoyagi K
    Hepatogastroenterology; 2010; 57(97):3-7. PubMed ID: 20422862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
    Hyder SA; Travis SP; Jewell DP; McC Mortensen NJ; George BD
    Dis Colon Rectum; 2006 Dec; 49(12):1837-41. PubMed ID: 17041753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of adalimumab therapy in multidisciplinary strategy for perianal Crohn's disease patients with infliximab failure.
    Echarri A; Castro J; Barreiro M; Carpio D; Pereira S; Lorenzo A
    J Crohns Colitis; 2010 Dec; 4(6):654-60. PubMed ID: 21122576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn's disease in patients treated with infliximab.
    Bouguen G; Trouilloud I; Siproudhis L; Oussalah A; Bigard MA; Bretagne JF; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2009 Oct; 30(7):749-56. PubMed ID: 19583709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI-based score helps in assessing the severity and in follow-up of pediatric patients with perianal Crohn disease.
    Kulkarni S; Gomara R; Reeves-Garcia J; Hernandez E; Restrepo R
    J Pediatr Gastroenterol Nutr; 2014 Feb; 58(2):252-7. PubMed ID: 24121148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism.
    Louis E; Vermeire S; Rutgeerts P; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Malaise M; Belaiche J
    Scand J Gastroenterol; 2002 Jul; 37(7):818-24. PubMed ID: 12190096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F
    Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective assessment of the effect on quality of life of anti-tumour necrosis factor therapy for perineal Crohn's fistulas.
    Ng SC; Plamondon S; Gupta A; Burling D; Kamm MA
    Aliment Pharmacol Ther; 2009 Oct; 30(7):757-66. PubMed ID: 19575762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping of T1-values and Gadolinium-concentrations in MRI as indicator of disease activity in luminal Crohn's disease: a feasibility study.
    Horsthuis K; Nederveen AJ; de Feiter MW; Lavini C; Stokkers PC; Stoker J
    J Magn Reson Imaging; 2009 Feb; 29(2):488-93. PubMed ID: 19161209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the modified Van Assche index for assessing response to anti-TNF therapy with MRI in perianal fistulizing Crohn's disease.
    van Rijn KL; Lansdorp CA; Tielbeek JAW; Nio CY; Buskens CJ; D'Haens GRAM; Löwenberg M; Stoker J
    Clin Imaging; 2020 Feb; 59(2):179-187. PubMed ID: 31821976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
    Vermeire S; Louis E; Carbonez A; Van Assche G; Noman M; Belaiche J; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Rutgeerts P;
    Am J Gastroenterol; 2002 Sep; 97(9):2357-63. PubMed ID: 12358256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of magnetic resonance imaging in evaluation of the activity of perianal Crohn's disease.
    Villa C; Pompili G; Franceschelli G; Munari A; Radaelli G; Maconi G; Cornalba GP
    Eur J Radiol; 2012 Apr; 81(4):616-22. PubMed ID: 21316171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas.
    Ng SC; Plamondon S; Gupta A; Burling D; Swatton A; Vaizey CJ; Kamm MA
    Am J Gastroenterol; 2009 Dec; 104(12):2973-86. PubMed ID: 19755971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of infliximab combined with surgery for perianal fistulizing Crohn's disease.
    Yang BL; Chen YG; Gu YF; Chen HJ; Sun GD; Zhu P; Shao WJ
    World J Gastroenterol; 2015 Feb; 21(8):2475-82. PubMed ID: 25741157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.